Arcutis Biotherapeutics, Inc. - Common Stock (ARQT)

Historical Holders from Q1 2020 to Q4 2025

Type / Class: Equity / Common Stock
Symbol: ARQT on Nasdaq
Shares outstanding: 120,138,422
Price per share: $29.04
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares: 125,769,778
Total reported value: $2,369,520,876
% of total 13F portfolios: 0%
Share change: -1,292,158
Value change: -$12,687,593
Number of holders: 233
Price from insider filings: $29.04

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
JENNISON ASSOCIATES LLC	10%	+6%	$230,991,369	+$16,837,739	12,254,119	+7.9%	Jennison Associates LLC	30 Sep 2025
PRUDENTIAL FINANCIAL INC	10%		$176,322,532		11,954,070		PRUDENTIAL FINANCIAL INC	31 Mar 2025
Frazier Life Sciences VIII, L.P.	7.5%		$130,399,321		8,943,712		Patrick J. Heron	18 Aug 2025
Polar Capital Holdings Plc	4.2%	-24%	$75,147,145	-$25,517,045	5,006,472	-25%	Polar Capital Holdings Plc	30 Jun 2025

As of 30 Sep 2025, Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) has 233 institutional shareholders filing 13F forms. They hold 125,769,778 shares. .

Top 25 institutional shareholders own 88% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
JENNISON ASSOCIATES LLC	10%	12,254,119	+10%	0.13%	$230,990,144
Rubric Capital Management LP	8.9%	10,749,457	0%	2.7%	$202,627,264
SUVRETTA CAPITAL MANAGEMENT, LLC	8.7%	10,478,000	-9.2%	6%	$197,510,300
Frazier Life Sciences Management, L.P.	8.2%	9,874,511	0%	5.6%	$186,134,532
BlackRock, Inc.	7.1%	8,573,995	+0.48%	0%	$161,619,806
VANGUARD GROUP INC	5.9%	7,146,090	+1.4%	0%	$134,703,797
Polar Capital Holdings Plc	4.4%	5,298,754	+5.8%	0.48%	$99,881,513
STATE STREET CORP	3.9%	4,641,315	+2.5%	0%	$87,488,788
GILDER GAGNON HOWE & CO LLC	3.7%	4,429,108	+6.6%	0.85%	$83,488,686
MORGAN STANLEY	3.6%	4,276,394	-0.88%	0%	$80,610,030
UBS Group AG	2.5%	2,948,438	+0.36%	0.01%	$55,578,057
GEODE CAPITAL MANAGEMENT, LLC	2.2%	2,606,465	+0.93%	0%	$49,139,527
JANUS HENDERSON GROUP PLC	2%	2,398,031	+5.9%	0.02%	$45,178,904
FRANKLIN RESOURCES INC	1.9%	2,311,019	-15%	0.01%	$43,562,708
Pivotal bioVenture Partners Investment Advisor LLC	1.8%	2,120,508	0%	23%	$39,971,576
D. E. Shaw & Co., Inc.	1.8%	2,118,713	-2%	0.03%	$39,937,740
Perpetual Ltd	1.7%	2,024,606	+7534%	0.47%	$38,163,823
Ensign Peak Advisors, Inc	1.7%	1,993,055	-0.42%	0.06%	$37,569,087
GOLDMAN SACHS GROUP INC	1.5%	1,804,988	-4.5%	0%	$34,024,024
AMERICAN CENTURY COMPANIES INC	1.4%	1,662,470	-3.6%	0.02%	$31,337,590
Nuveen, LLC	1.1%	1,370,356	+79%	0.01%	$25,831,211
GW&K Investment Management, LLC	0.98%	1,172,041	-15%	0.2%	$22,093,000
Driehaus Capital Management LLC	0.91%	1,097,004	+1%	0.15%	$20,678,525
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.83%	999,434	+3.6%	0%	$18,839,331
NORTHERN TRUST CORP	0.78%	940,202	+1.2%	0%	$17,722,808

Institutional Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	282,482	$8,200,136	+$6,361,694			$29.04	8
2025 Q3	125,769,778	$2,369,520,876	-$12,687,593	$2,503,280	$7,619,170	$18.85	233
2025 Q2	127,080,415	$1,781,069,063	+$21,637,125	$3,031,124	$5,710,116	$14.02	228
2025 Q1	125,020,441	$1,954,466,256	-$63,284,061	$2,658,800	$7,890,380	$15.64	239
2024 Q4	128,710,441	$1,792,934,402	+$13,789,213	$2,811,074	$6,230,889	$13.93	206
2024 Q3	128,641,664	$1,198,282,493	+$15,921,001	$762,600	$4,535,610	$9.30	187
2024 Q2	126,503,507	$1,176,619,915	+$9,242,287	$2,385,450	$3,990,820	$9.30	184
2024 Q1	124,986,945	$1,238,517,575	+$285,414,998	$8,036,019	$4,932,207	$9.91	166
2023 Q4	101,272,913	$327,119,655	+$79,248,549	$285,209	$175,066	$3.23	130
2023 Q3	67,159,664	$356,705,615	-$26,597,323	$1,045,539	$626,049	$5.31	131
2023 Q2	71,766,867	$683,988,878	-$5,745,956	$1,829,760	$3,452,719	$9.53	135
2023 Q1	71,600,840	$787,595,702	+$44,255,428	$1,127,500	$3,273,600	$11.00	141
2022 Q4	65,632,382	$971,340,873	+$87,400,990	$134,680	$8,846,600	$14.80	138
2022 Q3	59,389,299	$1,134,920,691	+$194,978,652	$338,000	$4,151,000	$19.11	138
2022 Q2	49,075,739	$1,045,833,934	+$17,642,019	$1,705,000	$3,862,000	$21.31	112
2022 Q1	48,307,139	$929,780,885	-$136,426,148	$289,000	$2,244,000	$19.26	106
2021 Q4	46,348,278	$961,255,152	-$1,852,441	$303,000	$1,363,000	$20.74	89
2021 Q3	45,697,453	$1,091,410,573	+$4,816,184	$480,000	$1,068,000	$23.89	103
2021 Q2	45,474,760	$1,240,848,739	-$38,040,013	$668,000	$2,866,000	$27.29	100
2021 Q1	46,841,365	$1,354,985,371	+$170,660,745	$321,000	$356,000	$28.93	93
2020 Q4	40,973,719	$1,152,598,120	+$138,537,380			$28.13	78
2020 Q3	34,766,158	$1,018,651,387	+$28,894,471			$29.30	62
2020 Q2	33,776,828	$1,021,408,758	+$33,104,690			$30.24	55
2020 Q1	32,683,658	$973,975,747	+$973,295,747			$29.80	49